Supernus Pharmaceuticals Q2 2024 GAAP EPS $0.36 Beats $0.05 Estimate, Sales $168.300M Beat $148.851M Estimate
Supernus Pharmaceuticals Q2 2024 GAAP EPS $0.36 Beats $0.05 Estimate, Sales $168.300M Beat $148.851M Estimate
supernus pharmaceuticals 2024年第二季度的GAAP每股收益爲0.36美元，超過0.05美元的估計值，銷售額爲1.683億美元，超過1.48851億美元的估計值。
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.05 by 620 percent. The company reported quarterly sales of $168.300 million which beat the analyst consensus estimate of $148.851 million by 13.07 percent. This is a 24.15 percent increase over sales of $135.563 million the same period last year.
Supernus Pharmaceuticals（納斯達克股票代碼SUPN）報告每股盈利0.36美元，超出分析師平均預期的0.05美元，增幅達620%。該公司季度銷售額爲1.683億美元，超出分析師平均預期的1.48851億美元，增幅爲13.07%。這是去年同期1.35563億美元銷售額的增長24.15%。